Drugs / PERAKIZUMAB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01199809 | Feb 2011 → Feb 2012 | psoriatic arthritis | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PERAKIZUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109470 ↗ |
| Known as | RG-4934 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109470 ↗ |
| Known as | RO5310074 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01199809 ↗ |
| Action | Inhibit | “Interleukin 17A inhibitor” CHEMBL2109470 ↗ |
| Modality | Monoclonal antibody | — CHEMBL2109470 ↗ |
| Route | Intravenous | “6 intravenous doses of RO5310074” NCT01199809 ↗ |
| Target | IL17A | “Interleukin 17A inhibitor” CHEMBL2109470 ↗ |